Výsledky vyhledávání - "Nancy S. Nicholson"

Aminopeptidase resistant Arg-Gly-Asp analogs are stable in plasma and inhibit platelet aggregation

Autor: S.G. Panzer-Knodle, Kam F. Fok, Larry P. Feigen, Steven Paul Adams, Nancy S. Nicholson, Foe S. Tjoeng

Publikováno v: International Journal of Peptide and Protein Research. 38:124-130

Tetrapeptides containing the sequence Arg-Gly-Asp (RGD) antagonize fibrinogen binding to its platelet receptor (gp IIb/IIIa, integrin alpha IIb beta 3) and inhibit platelet aggregation in vitro. The peptides RGDS and RGDY(Me)-NH2 were rapidly degrade

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d67a4cc0688e8be95fbe04ff42431fa
https://doi.org/10.1111/j.1399-3011.1991.tb01419.x

Zobrazit plný text záznamu

[Untitled]

Autor: James A. Szalony, Nancy S. Nicholson, Thomas J. Girard, Beatrice B. Taite, Rhonda M Lachance

Publikováno v: Journal of Thrombosis and Thrombolysis. 14:113-121

The Tissue Factor/Factor VIIa (TF/FVIIa) complex is an attractive target for pharmacological interruption of thrombin generation and hence blood coagulation, as this complex is the initiation point of the extrinsic pathway of coagulation. TF is a cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e157b22355e82669e3aed476ca94bb35
https://doi.org/10.1023/a:1023228827733

Zobrazit plný text záznamu

The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation

Autor: Nancy S. Nicholson, Thomas J. Girard

Publikováno v: Current Opinion in Pharmacology. 1:159-163

Tissue factor (TF) is the essential cofactor for the coagulation protease factor VIIa (FVIIa), initiating the coagulation cascade. The role of TF in thrombotic diseases is becoming increasingly evident. Recent findings suggest that inhibition of TF/F

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb6cfd9d72cabb1d787a8022f0811a8c
https://doi.org/10.1016/s1471-4892(01)00031-5

Zobrazit plný text záznamu

SC-54684A: An Orally Active Inhibitor of Platelet Aggregation

Autor: Jeffery Alan Zablocki, Neal F. Haas, Anita K. Salyers, S.G. Panzer-Knodle, Beatrice B. Taite, Larry P. Feigen, Marc Herin, Kay Broschat, Lucy W. King, Phillipe Jacqmin, Bradley T. Keller, V. Wayne Engleman, Nancy S. Nicholson, James A. Szalony

Publikováno v: Circulation. 91:403-410

Background Intravenous therapy has been shown to be beneficial in the prevention of acute platelet-associated thrombotic events. However, orally active agents would be advantageous for chronic therapy. Fibrinogen receptor antagonists block the fibrin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::336714372463ad6d39ffad92b62638ee
https://doi.org/10.1161/01.cir.91.2.403

Zobrazit plný text záznamu

Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents

Publikováno v: Bioorganic & Medicinal Chemistry. 2:881-895

The evolutionary process from the Arg-Gly-Asp-Phe (RGDF) tetrapeptide to potent orally active anti-platelet agents is presented. The RGD sequence is an important component in the recognition of fibrinogen by its platelet receptor GP IIb-IIIa (integri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82ff7ca1e73492c493b88cb344c8d089
https://doi.org/10.1016/s0968-0896(00)82038-6

Zobrazit plný text záznamu

Fibrinogen receptor antagonists

Autor: Larry P. Feigen, Nancy S. Nicholson, Jeffery Alan Zablocki

Publikováno v: Expert Opinion on Investigational Drugs. 3:437-448

Fibrinogen receptor antagonists represent a potential new form of antithrombotic therapy for the treatment or prevention of vascular complications including: myocardial infarct, unstable angina, stroke and complications during percutaneous translumin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed98ef05fd0ed987610c6fdd1530a1e5
https://doi.org/10.1517/13543784.3.5.437

Zobrazit plný text záznamu

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor

Autor: Nancy S. Nicholson, Jeffery Alan Zablocki, R. J. Lindmark, D Pireh, Robert Bruce Garland, Beatrice B. Taite, Masateru Miyano, Shashidhar N. Rao, L Schretzman, S.G. Panzer-Knodle

Publikováno v: Journal of Medicinal Chemistry. 36:1811-1819

Peptide mimetics of the RGDF sequence in which Arg-Gly has been replaced with 5-(4-amidinophenyl)pentanoyl mimetic has led to a 1000-fold increase in inhibitory potency over the natural RGDF ligand. The guanidine residue of the arginine may be involv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d418001710ed44efdbaa4f9aa830654d
https://doi.org/10.1021/jm00065a003

Zobrazit plný text záznamu

Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIa

Autor: Larry P. Feigen, S.G. Panzer-Knodle, P. Jacqmin, V. W. Engleman, J. D. Page, Nancy S. Nicholson, Jeffery Alan Zablocki

Publikováno v: Platelets. 6(5)

In order to compare binding of small peptide mimetics on activated vs resting platelets and with fibrinogen (fgn) on activated platelets, the binding of [(3)H]-SC-52012, a low molecular weight (483) mimetic of the RGDF sequence present in fgn, was ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2d2811bc34d9832d3335c7dc3f49dfc
https://pubmed.ncbi.nlm.nih.gov/21043715

Zobrazit plný text záznamu

ChemInform Abstract: Orbofiban: An Orally Active GPIIb/IIIa Platelet Receptor Antagonist

Autor: Norman A. Abood, Anita K. Salyers, Beatrice B. Taite, Susan G. Panzer-Knodle, Osman D. Suleymanov, Nancy S. Nicholson, Leo G. Frederick, Robert J. Anders, James A. Szalony, Jimmy D. Page

Publikováno v: ChemInform. 32

A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes, and restenosis after percutaneous interventions. Antiplatelet agents that have a wider spectrum of activity than aspirin,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::612943204336f54d9eb2fc9fd7c09e63
https://doi.org/10.1002/chin.200127240

Zobrazit plný text záznamu

A method for determining whether hypotension caused by novel compounds in preclinical development results from histamine release

Autor: Craig D. Wegner, Po-Chang Yang, Case Brenda, Nancy S. Nicholson, South Michael S, Jason D. Blom, John J. Parlow

Publikováno v: Journal of pharmacological and toxicological methods. 49(1)

Introduction: Many therapeutic agents stimulate histamine release from mast cells, which results in a decrease in blood pressure. The purpose of this study is to establish a method to determine if the mechanism of action, or one of the mechanisms, of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::090be0555be854d2bc026ad1f8c07ece
https://pubmed.ncbi.nlm.nih.gov/14670692

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání